Published in Expert Rev Mol Diagn on November 11, 2015
AZD8186 First Time In Patient Ascending Dose Study | NCT01884285
Pembrolizumab and Monoclonal Antibody Therapy in Advanced Cancer (PembroMab) | NCT02318901
PLX3397 KIT in Acral aNd mucOsal Melanoma (PIANO) | NCT02071940
Study of Pembrolizumab Plus Chemotherapy in Patients With Advanced Cancer (PembroPlus) | NCT02331251
Tumor Specific Plasma DNA | NCT01617915
Molecular Diagnosis on Circulating Tumor DNA of Non-Small Cell Lung Cancer (ANTiCIPe) | NCT02169349
NGS Genome Analysis in Personalisation of Lung Cancer Treatment (ALCAPONE) | NCT02281214
Presence of Circulating Tumor DNA in Colorectal Cancer (ALGECOLS) | NCT01198743
Circulating Cell-free DNA as a Predictive Biomarker for Hepatocelluar Carcinoma. | NCT02036216
Analysis of Circulating Tumor DNA to Monitor Metastatic Colorectal Cancer Treatment | NCT01983098
Detection of CF-DNA in Patients With Gastrointestinal Stromal Tumors (GIST) | NCT01462994
Analysis of Plasma Tumor DNA in Lung Cancer Patients | NCT01930474
The Oncopanel Pilot (TOP) Study | NCT02171286
GIST: Assessment of Tumor Mutations and TKI Plasma Exposure | NCT02331914
Current status of biomarker research in neurology. EPMA J (2016) 0.79
Cell-Free DNA Provides a Good Representation of the Tumor Genome Despite Its Biased Fragmentation Patterns. PLoS One (2017) 0.75
Detection of Histone H3 mutations in cerebrospinal fluid-derived tumor DNA from children with diffuse midline glioma. Acta Neuropathol Commun (2017) 0.75
Detection of copy number alterations in cell-free tumor DNA from plasma. BBA Clin (2017) 0.75
Prognostic Significance of Circulating RET M918T Mutated Tumor DNA in Patients With Advanced Medullary Thyroid Carcinoma. J Clin Endocrinol Metab (2017) 0.75
Mutation-Enrichment Next-Generation Sequencing for Quantitative Detection of KRAS Mutations in Urine Cell-Free DNA from Patients with Advanced Cancers. Clin Cancer Res (2017) 0.75
Mystery of the brain metastatic disease in breast cancer patients: improved patient stratification, disease prediction and targeted prevention on the horizon? EPMA J (2017) 0.75
Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med (2012) 44.56
Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med (2004) 27.92
Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer. Clin Cancer Res (2008) 14.37
Analysis of circulating tumor DNA to monitor metastatic breast cancer. N Engl J Med (2013) 13.22
Tumor metastasis: molecular insights and evolving paradigms. Cell (2011) 10.34
Circulating mutant DNA to assess tumor dynamics. Nat Med (2007) 10.33
The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers. Nature (2012) 10.17
Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer. Nature (2012) 8.77
Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer. J Clin Oncol (2008) 8.72
EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors. N Engl J Med (2010) 8.59
Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci Transl Med (2014) 8.36
The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP. Proc Natl Acad Sci U S A (2008) 8.08
Cell-free nucleic acids as biomarkers in cancer patients. Nat Rev Cancer (2011) 7.69
Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA. Nature (2013) 7.42
Detection and quantification of mutations in the plasma of patients with colorectal tumors. Proc Natl Acad Sci U S A (2005) 5.91
Noninvasive identification and monitoring of cancer mutations by targeted deep sequencing of plasma DNA. Sci Transl Med (2012) 5.69
DNA fragments in the blood plasma of cancer patients: quantitations and evidence for their origin from apoptotic and necrotic cells. Cancer Res (2001) 5.45
An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage. Nat Med (2014) 4.98
Circulating tumor cells at each follow-up time point during therapy of metastatic breast cancer patients predict progression-free and overall survival. Clin Cancer Res (2006) 4.95
Liquid biopsies: genotyping circulating tumor DNA. J Clin Oncol (2014) 4.76
Circulating nucleic acids (CNAs) and cancer--a survey. Biochim Biophys Acta (2006) 4.60
Detection of cancer DNA in plasma of patients with early-stage breast cancer. Clin Cancer Res (2014) 3.50
Single-molecule detection of epidermal growth factor receptor mutations in plasma by microfluidics digital PCR in non-small cell lung cancer patients. Clin Cancer Res (2009) 3.41
Cancer genome scanning in plasma: detection of tumor-associated copy number aberrations, single-nucleotide variants, and tumoral heterogeneity by massively parallel sequencing. Clin Chem (2012) 3.35
Liquid biopsy: monitoring cancer-genetics in the blood. Nat Rev Clin Oncol (2013) 3.34
[Not Available]. C R Seances Soc Biol Fil (1948) 3.32
Noninvasive detection of response and resistance in EGFR-mutant lung cancer using quantitative next-generation genotyping of cell-free plasma DNA. Clin Cancer Res (2014) 3.28
Evolution of the cancer genome. Nat Rev Genet (2012) 3.24
Detection of aberrant promoter hypermethylation of tumor suppressor genes in serum DNA from non-small cell lung cancer patients. Cancer Res (1999) 3.15
Tumor clone dynamics in lethal prostate cancer. Sci Transl Med (2014) 2.93
Pretreatment epidermal growth factor receptor (EGFR) T790M mutation predicts shorter EGFR tyrosine kinase inhibitor response duration in patients with non-small-cell lung cancer. J Clin Oncol (2012) 2.91
Targeting RAF kinases for cancer therapy: BRAF-mutated melanoma and beyond. Nat Rev Cancer (2014) 2.54
Tumor-associated copy number changes in the circulation of patients with prostate cancer identified through whole-genome sequencing. Genome Med (2013) 2.28
Gefitinib treatment in EGFR mutated caucasian NSCLC: circulating-free tumor DNA as a surrogate for determination of EGFR status. J Thorac Oncol (2014) 2.23
Quantitative detection of EGFR mutations in circulating tumor DNA derived from lung adenocarcinomas. Clin Cancer Res (2011) 2.23
Detection of aberrant p16 methylation in the plasma and serum of liver cancer patients. Cancer Res (1999) 2.19
Detection of tumor PIK3CA status in metastatic breast cancer using peripheral blood. Clin Cancer Res (2012) 2.07
Identification of double-stranded genomic DNA spanning all chromosomes with mutated KRAS and p53 DNA in the serum exosomes of patients with pancreatic cancer. J Biol Chem (2014) 1.92
Clinical validation of the detection of KRAS and BRAF mutations from circulating tumor DNA. Nat Med (2014) 1.78
Analysis of circulating tumor DNA in plasma at diagnosis and during follow-up of lung cancer patients. Cancer Res (2001) 1.76
Degradation of chromosomal DNA during apoptosis. Cell Death Differ (2003) 1.73
Tumor-specific p53 sequences in blood and peritoneal fluid of women with epithelial ovarian cancer. Am J Obstet Gynecol (2005) 1.72
Prognostic significance of methylated RASSF1A and PITX2 genes in blood- and bone marrow plasma of breast cancer patients. Breast Cancer Res Treat (2011) 1.71
Increased plasma DNA integrity in cancer patients. Cancer Res (2003) 1.59
Detection of PIK3CA mutations in circulating free DNA in patients with breast cancer. Breast Cancer Res Treat (2010) 1.59
Dynamic plasma EGFR mutation status as a predictor of EGFR-TKI efficacy in patients with EGFR-mutant lung adenocarcinoma. J Thorac Oncol (2015) 1.59
Non-invasive prenatal testing for aneuploidy: current status and future prospects. Ultrasound Obstet Gynecol (2013) 1.58
K-ras mutations in DNA extracted from the plasma of patients with pancreatic carcinoma: diagnostic utility and prognostic significance. J Clin Oncol (1999) 1.53
Quantitative cell-free DNA, KRAS, and BRAF mutations in plasma from patients with metastatic colorectal cancer during treatment with cetuximab and irinotecan. Clin Cancer Res (2012) 1.51
High fragmentation characterizes tumour-derived circulating DNA. PLoS One (2011) 1.42
Utility of circulating B-RAF DNA mutation in serum for monitoring melanoma patients receiving biochemotherapy. Clin Cancer Res (2007) 1.33
Prospective blinded study of BRAFV600E mutation detection in cell-free DNA of patients with systemic histiocytic disorders. Cancer Discov (2014) 1.33
Plasma circulating tumor DNA as an alternative to metastatic biopsies for mutational analysis in breast cancer. Ann Oncol (2014) 1.31
Quantification and dynamic monitoring of EGFR T790M in plasma cell-free DNA by digital PCR for prognosis of EGFR-TKI treatment in advanced NSCLC. PLoS One (2014) 1.30
Origin and quantification of circulating DNA in mice with human colorectal cancer xenografts. Nucleic Acids Res (2010) 1.28
Circulating plasma DNA as diagnostic biomarker in non-small cell lung cancer. Lung Cancer (2008) 1.25
Cell-free nucleic acids circulating in the plasma of colorectal cancer patients induce the oncogenic transformation of susceptible cultured cells. Cancer Res (2010) 1.24
Detection of K-ras gene mutations in plasma DNA of patients with pancreatic adenocarcinoma: correlation with clinicopathological features. Clin Cancer Res (1998) 1.24
Potential clinical significance of a plasma-based KRAS mutation analysis in patients with advanced non-small cell lung cancer. Clin Cancer Res (2010) 1.23
Comparison of circulating plasma DNA levels between lung cancer patients and healthy controls. J Mol Diagn (2009) 1.19
Characterizing the patterns of clonal selection in circulating tumor DNA from patients with colorectal cancer refractory to anti-EGFR treatment. Ann Oncol (2015) 1.18
Detection and monitoring of cell-free DNA in blood of patients with colorectal cancer. Ann N Y Acad Sci (2008) 1.17
Circulating cell free DNA: Preanalytical considerations. Clin Chim Acta (2013) 1.16
Implications of BCR-ABL1 kinase domain-mediated resistance in chronic myeloid leukemia. Leuk Res (2013) 1.16
Effect of DNA size and strandedness on the in vivo clearance and organ localization of DNA. Clin Exp Immunol (1984) 1.15
The value of serial plasma nuclear and mitochondrial DNA levels in patients with acute ischemic stroke. Clin Chim Acta (2010) 1.11
Quantitative and qualitative characterization of plasma DNA identifies primary and recurrent colorectal cancer. Cancer Lett (2008) 1.11
Mechanism-based cancer therapy: resistance to therapy, therapy for resistance. Oncogene (2014) 1.10
Circulating tumor cells and circulating tumor DNA for precision medicine: dream or reality? Ann Oncol (2014) 1.09
Tumor DNA in plasma at diagnosis of breast cancer patients is a valuable predictor of disease-free survival. Clin Cancer Res (2002) 1.08
Plasma cell-free DNA in ovarian cancer: an independent prognostic biomarker. Cancer (2010) 1.07
Role of early cell-free DNA levels decrease as a predictive marker of fatal outcome after severe traumatic brain injury. Clin Chim Acta (2012) 1.06
Molecular detection of APC, K- ras, and p53 mutations in the serum of colorectal cancer patients as circulating biomarkers. World J Surg (2004) 1.05
Molecular diagnostics and personalized medicine in oncology: challenges and opportunities. J Cell Biochem (2013) 1.04
Clinical significance of promoter hypermethylation of DNA repair genes in tumor and serum DNA in invasive ductal breast carcinoma patients. Life Sci (2010) 1.04
Aberrant DNA methylation of the p16INK4a gene in plasma DNA of breast cancer patients. Br J Cancer (1999) 1.03
Diagnostic and prognostic value of circulating tumor-related DNA in cancer patients. Expert Rev Mol Diagn (2013) 1.02
The prognostic value of KRAS mutated plasma DNA in advanced non-small cell lung cancer. Lung Cancer (2012) 1.02
Loss of heterozygosity at tumor suppressor genes detectable on fractionated circulating cell-free tumor DNA as indicator of breast cancer progression. Clin Cancer Res (2012) 1.01
Optimizing blood collection, transport and storage conditions for cell free DNA increases access to prenatal testing. Clin Biochem (2013) 1.01
Cell-Free DNA Next-Generation Sequencing in Pancreatobiliary Carcinomas. Cancer Discov (2015) 1.01
Levels of circulating cell-free nuclear and mitochondrial DNA in benign and malignant ovarian tumors. Obstet Gynecol (2008) 0.99
Free circulating tumor DNA as a diagnostic marker for breast cancer. J Clin Lab Anal (2012) 0.98
Fine-needle aspiration (FNA) biopsy: historical aspects. Folia Histochem Cytobiol (2009) 0.97
BRAF V600E mutations in urine and plasma cell-free DNA from patients with Erdheim-Chester disease. Oncotarget (2014) 0.96
Acquired resistance to EGFR-targeted therapies in colorectal cancer. Mol Oncol (2014) 0.96
Brain tumor mutations detected in cerebral spinal fluid. Clin Chem (2015) 0.96
Prognostic role of methylated free circulating DNA in colorectal cancer. Int J Cancer (2012) 0.95
Analysis of cancer mutation signatures in blood by a novel ultra-sensitive assay: monitoring of therapy or recurrence in non-metastatic breast cancer. PLoS One (2009) 0.94
Prognostic value of circulating mutant DNA in unresectable metastatic colorectal cancer. Ann Surg (2010) 0.94
Free circulating DNA as possible tumour marker in colorectal cancer. Surg Oncol (2007) 0.94
Quantification of free circulating tumor DNA as a diagnostic marker for breast cancer. DNA Cell Biol (2008) 0.93
Evaluation of fluorescence-based methods for total vs. amplifiable DNA quantification in plasma of lung cancer patients. J Physiol Pharmacol (2008) 0.92
A rapid direct fluorescent assay for cell-free DNA quantification in biological fluids. Ann Clin Biochem (2009) 0.92
Actionable mutations in plasma cell-free DNA in patients with advanced cancers referred for experimental targeted therapies. Oncotarget (2015) 0.92
LOH at 6q and 10q in fractionated circulating DNA of ovarian cancer patients is predictive for tumor cell spread and overall survival. BMC Cancer (2012) 0.91
A novel blood collection device stabilizes cell-free RNA in blood during sample shipping and storage. BMC Res Notes (2013) 0.90
Allelic imbalance on 12q22-23 in serum circulating DNA of melanoma patients predicts disease outcome. Cancer Res (2004) 0.90
Multiple marker detection in peripheral blood for NSCLC diagnosis. PLoS One (2013) 0.89
A sensitive method to quantify human cell-free circulating DNA in blood: relevance to myocardial infarction screening. Clin Biochem (2011) 0.87
Personalized medicine in a phase I clinical trials program: the MD Anderson Cancer Center initiative. Clin Cancer Res (2012) 3.14
Concurrent versus sequential chemoradiotherapy with cisplatin and vinorelbine in locally advanced non-small cell lung cancer: a randomized study. Lung Cancer (2004) 2.38
BRAF mutations in advanced cancers: clinical characteristics and outcomes. PLoS One (2011) 1.40
Validation of the Royal Marsden Hospital prognostic score in patients treated in the Phase I Clinical Trials Program at the MD Anderson Cancer Center. Cancer (2011) 1.37
Unique molecular signatures as a hallmark of patients with metastatic breast cancer: implications for current treatment paradigms. Oncotarget (2014) 1.34
A phase I trial of liposomal doxorubicin, bevacizumab, and temsirolimus in patients with advanced gynecologic and breast malignancies. Clin Cancer Res (2011) 1.26
P53 mutations in advanced cancers: clinical characteristics, outcomes, and correlation between progression-free survival and bevacizumab-containing therapy. Oncotarget (2013) 1.26
Adjuvant interferon in high-risk melanoma: end of the era? J Clin Oncol (2009) 1.01
Successful treatment of Castleman's disease with interleukin-1 receptor antagonist (Anakinra). Mol Cancer Ther (2010) 1.00
KRASness and PIK3CAness in patients with advanced colorectal cancer: outcome after treatment with early-phase trials with targeted pathway inhibitors. PLoS One (2012) 0.96
Anastrozole and everolimus in advanced gynecologic and breast malignancies: activity and molecular alterations in the PI3K/AKT/mTOR pathway. Oncotarget (2014) 0.95
Targeted therapy of advanced gallbladder cancer and cholangiocarcinoma with aggressive biology: eliciting early response signals from phase 1 trials. Oncotarget (2013) 0.94
Biomarker-directed therapy of squamous carcinomas of the head and neck: targeting PI3K/PTEN/mTOR pathway. J Clin Oncol (2013) 0.94
Prognostic indicators and treatment outcome in 94 cases of fibrolamellar hepatocellular carcinoma. Oncology (2013) 0.91
Revisiting clinical trials using EGFR inhibitor-based regimens in patients with advanced non-small cell lung cancer: a retrospective analysis of an MD Anderson Cancer Center phase I population. Oncotarget (2013) 0.89
Thymoma patients treated in a phase I clinic at MD Anderson Cancer Center: responses to mTOR inhibitors and molecular analyses. Oncotarget (2013) 0.89
STAT3 inhibitors: finding a home in lymphoma and leukemia. Oncologist (2014) 0.88
Phase I combination of pazopanib and everolimus in PIK3CA mutation positive/PTEN loss patients with advanced solid tumors refractory to standard therapy. Invest New Drugs (2015) 0.88
Barriers to study enrollment in patients with advanced cancer referred to a phase I clinical trials unit. Oncologist (2013) 0.88
Target-based therapeutic matching in early-phase clinical trials in patients with advanced colorectal cancer and PIK3CA mutations. Mol Cancer Ther (2013) 0.87
Germline PTPRD mutations in Ewing sarcoma: biologic and clinical implications. Oncotarget (2013) 0.87
Non-small-cell lung cancer with HER2 exon 20 mutation: regression with dual HER2 inhibition and anti-VEGF combination treatment. J Thorac Oncol (2013) 0.87
Phase I study of anti-VEGF monoclonal antibody bevacizumab and histone deacetylase inhibitor valproic acid in patients with advanced cancers. Cancer Chemother Pharmacol (2014) 0.85
Exploratory study of carboplatin plus the copper-lowering agent trientine in patients with advanced malignancies. Invest New Drugs (2013) 0.84
Patients with advanced head and neck cancers have similar progression-free survival on phase I trials and their last food and drug administration-approved treatment. Clin Cancer Res (2010) 0.84
A novel immunomodulatory molecularly targeted strategy for refractory Hodgkin's lymphoma. Oncotarget (2014) 0.84
MET aberrations and c-MET inhibitors in patients with gastric and esophageal cancers in a phase I unit. Oncotarget (2014) 0.83
Outcomes of patients with metastatic cervical cancer in a phase I clinical trials program. Anticancer Res (2014) 0.82
A pilot study of temsirolimus and body composition. J Cachexia Sarcopenia Muscle (2013) 0.82
Phase I clinical trial of bendamustine and bevacizumab for patients with advanced cancer. J Natl Compr Canc Netw (2014) 0.81
Targeted therapy of advanced gallbladder cancer and cholangiocarcinoma with aggressive biology: eliciting early response signals from phase 1 trials. Oncotarget (2013) 0.80
Ridaforolimus in advanced sarcomas: a leap forward or missed opportunity? J Clin Oncol (2012) 0.78
Retreatment after secondary resistance or mixed response: a pilot study. Oncology (2013) 0.77
Symptomatic control of hypoglycaemia with prednisone in refractory metastatic pancreatic insulinoma. Support Care Cancer (2005) 0.77
Characteristics and survival of patients with advanced cancer and p53 mutations. Oncotarget (2014) 0.77
Olanzapine for cachexia in patients with advanced cancer: an exploratory study of effects on weight and metabolic cytokines. Support Care Cancer (2015) 0.77
Bringing target-matched PI3King from the bench to the clinic. Cell Cycle (2013) 0.76
Phase I clinical trial of lenalidomide in combination with temsirolimus in patients with advanced cancer. Invest New Drugs (2013) 0.76
Dual antiangiogenic inhibition: a phase I dose escalation and expansion trial targeting VEGF-A and VEGFR in patients with advanced solid tumors. Invest New Drugs (2014) 0.76
Xilonix, a novel true human antibody targeting the inflammatory cytokine interleukin-1 alpha, in non-small cell lung cancer. Invest New Drugs (2015) 0.75
Personalized medicine in advanced non-small-cell lung cancer: reality or wishful thinking? J Clin Oncol (2008) 0.75
Phase I clinical trial of lenalidomide in combination with sorafenib in patients with advanced cancer. Invest New Drugs (2013) 0.75
Post-Discharge Survival Outcomes of Patients with Advanced Cancer from the University of Texas MD Anderson Cancer Center Investigational Cancer Therapeutics (Phase I Trials) Inpatient Unit. Oncology (2016) 0.75
Dose-finding study of hepatic arterial infusion of irinotecan-based treatment in patients with advanced cancers metastatic to the liver. Invest New Drugs (2015) 0.75
A phase I trial of combination trastuzumab, lapatinib, and bevacizumab in patients with advanced cancer. Invest New Drugs (2014) 0.75
First-in-human trial of multikinase VEGF inhibitor regorafenib and anti-EGFR antibody cetuximab in advanced cancer patients. JCI Insight (2017) 0.75
Highlights from the 7th central European lung cancer conference. Lung Cancer (2002) 0.75
Erratum: Actionable mutations in plasma cell-free DNA in patients with advanced cancers referred for experimental targeted therapies. Oncotarget (2015) 0.75
A phase I study of pemetrexed (ALIMTA) and cyclophosphamide in patients with locally advanced or metastatic breast cancer. Clin Cancer Res (2006) 0.75
Quantification of the Effect of Shuttling on Computed Tomography Perfusion Parameters by Investigation of Aortic Inputs on Different Table Positions From Shuttle-Mode Scans of Lung and Liver Tumors. J Comput Assist Tomogr (2017) 0.75